Forteo ® (teriparatide [rDNA origin] injection)

20-mcg daily dose in a 2.4-mL prefilled delivery device

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

FORTEO® (teriparatide [rDNA origin]): Adverse Reactions Associated With Abruptly Stopping

Safety concerns associated with temporary interruption or abrupt discontinuation of FORTEO® therapy have not been identified.

Detailed Information

Safety concerns associated with temporary interruption or abrupt discontinuation of teriparatide therapy have not been identified.

Lilly has not identified any safety concerns, including adverse reactions or side effects, associated with temporary interruption or withdrawal of teriparatide therapy during our clinical studies or follow-up analyses.1-6

It is not known how stopping and starting teriparatide affects how it works as teriparatide was studied as a once-daily injection without interruptions for 24 months.7

Inform your physician if you had to stop teriparatide for any period of time.

Enclosed Prescribing Information

FORTEO® (teriparatide [rDNA origin] injection), Lilly

References

The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).

1. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434-1441. http://dx.doi.org/10.1056/nejm200105103441904

2. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18(1):9-17. http://dx.doi.org/10.1359/jbmr.2003.18.1.9

3. Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004;164(18):2024-2030. http://dx.doi.org/10.1001/archinte.164.18.2024

4. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028-2039. http://dx.doi.org/10.1056/NEJMoa071408

5. Silverman S, Miller P, Sebba A, et al. The direct assessment of nonvertebral fractures in community experience (DANCE) study: 2-year nonvertebral fragility fracture results. Osteoporos Int. 2013;24(8):2309-2317. http://dx.doi.org/10.1007/s00198-013-2284-y

6. Saag KG, Zanchetta JR, Devogelaer JP, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346-3355. http://dx.doi.org/10.1002/art.24879

7. Forteo [package insert]. Indianapolis IN: Eli Lilly and Company; 2019.

Glossary

Lilly = Eli Lilly and Company

Date of Last Review: November 11, 2019

Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 8am - 7pm ET

Or you can

Ask us a question Chat with us

Submit a Request

Visit Us @LillyMedical